Le Lézard
Classified in: Covid-19 virus
Subjects: MAV, CMG, CFG

/R E P E A T -- Media Advisory: Infrastructure Announcement in Moncton/


MONCTON, NB, June 24, 2021 /CNW/ - Members of the media are invited to an important announcement regarding COVID-19 response infrastructure investments with the Honourable Ginette Petitpas Taylor, Member of Parliament for Moncton?Riverview?Dieppe, on behalf of to the Honourable Catherine McKenna, Minister of Infrastructure and Communities; and Her Worship Dawn Arnold, Mayor of the City of Moncton.

Date:

Friday, June 25, 2021 



Time:

9:30 a.m. ADT



Location: 

Centennial Park
Lower Bowl (near site of old Centennial Beach) 
811 St George Boulevard
Moncton, New Brunswick

Follow us on Twitter, Facebook, Instagram, and LinkedIn 
Web: Infrastructure Canada

SOURCE Infrastructure Canada


These press releases may also interest you

at 02:28
Pet Insurance Market to Reach $38.3 billion, Globally, by 2033 at 14.5% CAGR: Allied Market Research
Allied Market Research published a report, titled, "Pet Insurance Market by Policy Coverage (Accident Only, Accident and Illness, and Others), Animal Type (Dogs, Cats, and Others), and Sales Channel (Agency, Broker, and Others): Global...

at 02:00
Bradda Head Lithium Ltd Announces Settlement Agreement Over Fraudulent Payment
Bradda Head Lithium Ltd (AIM:BHL), the North America-focused lithium development group, is pleased to announce that it has come to a settlement regarding the fraudulent payment first notified on 29 March 2022 and subsequently disclosed in the audited...

at 00:25
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab Limited and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of...

19 mai 2024
ICIS announces the 16th Asian Base Oils and Lubricants Conference in Singapore
ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential...

19 mai 2024
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

19 mai 2024
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Amgen and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood...

More news about Covid-19 virus...


News published on and distributed by: